In recent years, tumor immunotherapy has become the core of cancer treatment research. With innovation as the driving force, Medicilon has vigorously developed a tumor immunity (Immuno-oncology) drug efficacy evaluation research platform. Currently, CAR-T, TCR-T, CAR-NK, Oncolytic Virus, antibodies (monoclonal antibodies, double antibodies, polyclonal antibodies, etc.), siRNA, AAV, and other immunotherapy models and methods for evaluating the efficacy of immunotherapy, empower the research process of innovative therapies and protect health!
The homologous tumor transplantation model tests the ability of model animals to use their perfect immune system to fight cancer and the therapeutic effect of immunotherapy.The choices we offer you are:
Classification of immune cells in model blood by flow cytometry
The humanized tumor mouse model of a partially reorganized human immune system is particularly effective for short-term or high-throughput research.
The types of models currently available for Medicilon are:
Tumor growth and drug efficacy evaluation of PBMC humanized mouse lymphoma transplantation model.
Humanized mice transplanted with CD34+ human umbilical cord blood cells to reconstruct the human hematopoietic system are colonized in the mouse bone marrow and continuously and stably produce various human hematopoietic cells and immune cells and use the human immune system to evaluate multiple immunotherapy.
Medicilon’s currently available models are:
The xenogeneic orthotopic tumor transplantation model can fully consider the interaction of tumor cells and the organ microenvironment between the surrounding stroma and monitor tumor growth when evaluating drug efficacy.
Medicilon will break the barriers of experimentation and technology for you. At present, it has mature orthotopic transplantation technology, including orthotopic brain transplantation, orthotopic liver transplantation, orthotopic lung transplantation, orthotopic transplantation of tibia marrow cavity, orthotopic intravesical transplantation Transplant, etc.
The human tumor transplantation model PDX retains the characteristics of the patient’s tumor tissue and is more clinically relevant. It can establish an ideal tumor immunotherapy evaluation model combined with humanized mice. Medicilon has now developed:
Medicilon’s PDX model research includes molecular-level genotyping and tumor model pharmacological efficacy evaluation services, providing a highly predictive model for clinical efficacy study.
The new anti-tumor weapon PDX model helps the development of new immune cancer drugs
contact us
Email: marketing@medicilon.com
Tel: +86 (21) 5859-1500
Relevant
news
marketing@medicilon.com
